Answers are grounded in this paper and cite their sources.
Findings show intrahepatic tumor burden affects overall survival in hepatocellular carcinoma, suggesting a need for improved treatment strategies.
In metastatic HCC treated with atezolizumab plus bevacizumab, intrahepatic tumor burden was associated with overall survival and may be useful for risk stratification and treatment optimization.
No takes yet. Share an insight, caveat, or question.
Tanaka et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: